News

top of page

United European Gastroenterology Week | 2026

United European Gastroenterology Week | 2026

United European Gastroenterology Week | 2026

Badari Andukuri

6 days ago

FDA Clears Roche’s Enspryng for Thyroid Eye Disease, Introducing Home-Based Injection Option

FDA Clears Roche’s Enspryng for Thyroid Eye Disease, Introducing Home-Based Injection Option

FDA Clears Roche’s Enspryng for Thyroid Eye Disease, Introducing Home-Based Injection Option

Badari Andukuri

6 days ago

American College of Gastroenterology | Annual Scientific Meeting | 2026

American College of Gastroenterology | Annual Scientific Meeting | 2026

American College of Gastroenterology | Annual Scientific Meeting | 2026

Badari Andukuri

Oct 14

European Academy of Dermatology and Venereology Congress | 2026

Badari Andukuri

Oct 4

International Myeloma Society (IMS) Annual Meeting 2026

International Myeloma Society (IMS) Annual Meeting 2026

International Myeloma Society (IMS) Annual Meeting 2026

Badari Andukuri

Sep 27

FDA Clears Welireg and Lenvima Combination for Advanced Clear Cell Kidney Cancer After Immunotherapy

Badari Andukuri

Sep 27

IASLC 2026 World Conference on Lung Cancer (#WCLC26) | 2026 | iPharmaCenter

IASLC 2026 World Conference on Lung Cancer (#WCLC26) | 2026 | iPharmaCenter

IASLC 2026 World Conference on Lung Cancer (#WCLC26) | 2026 | iPharmaCenter

Badari Andukuri

Sep 15

Pharmaceutical Healthcare Deals & Acquisitions - 2026 | iPharmaCenter

Pharmaceutical Healthcare Deals & Acquisitions - 2026 | iPharmaCenter

Pharmaceutical Healthcare Deals & Acquisitions - 2026 | iPharmaCenter

Badari Andukuri

Sep 15

European Respiratory Society Congress 2026 | iPharmaCenter

European Respiratory Society Congress 2026 | iPharmaCenter

European Respiratory Society Congress 2026 | iPharmaCenter

Badari Andukuri

Sep 10

German Public Health Insurance Posts €2.6 Billion Surplus in First Half of 2026, But Underlying Deficit Persists as Hospital Costs Surge 9.3 Percent

German Public Health Insurance Posts €2.6 Billion Surplus in First Half of 2026, But Underlying Deficit Persists as Hospital Costs Surge 9.3 Percent

German Public Health Insurance Posts €2.6 Billion Surplus in First Half of 2026, But Underlying Deficit Persists as Hospital Costs Surge 9.3 Percent

Badari Andukuri

Sep 5

FDA Clears AstraZeneca's Etcamah for a Genetically Defined Subset of First-Line Breast Cancer | iPharmaCenter

FDA Clears AstraZeneca's Etcamah for a Genetically Defined Subset of First-Line Breast Cancer | iPharmaCenter

FDA Clears AstraZeneca's Etcamah for a Genetically Defined Subset of First-Line Breast Cancer | iPharmaCenter

Badari Andukuri

Sep 5

Ionis Wins First Ever FDA Approval for an Alexander Disease Treatment, Marking a Turning Point for a Disease With No Prior Options

Ionis Wins First Ever FDA Approval for an Alexander Disease Treatment, Marking a Turning Point for a Disease With No Prior Options

Ionis Wins First Ever FDA Approval for an Alexander Disease Treatment, Marking a Turning Point for a Disease With No Prior Options

Badari Andukuri

Sep 4

European Commission | EMA Drug Approvals | 2026 | iPharmaCenter

European Commission | EMA Drug Approvals | 2026 | iPharmaCenter

European Commission | EMA Drug Approvals | 2026 | iPharmaCenter

Badari Andukuri

Sep 3

European Society of Cardiology (ESC) Congress 2026 | News | Updates | iPharmaCenter

European Society of Cardiology (ESC) Congress 2026 | News | Updates | iPharmaCenter

European Society of Cardiology (ESC) Congress 2026 | News | Updates | iPharmaCenter

Badari Andukuri

Sep 1

INDIAN HEALTHCARE SYSTEM | HEALTHCARE SYSTEM OF INDIA | NEWS | BLOGS | IPHARMACENTER

INDIAN HEALTHCARE SYSTEM | HEALTHCARE SYSTEM OF INDIA | NEWS | BLOGS | IPHARMACENTER

INDIAN HEALTHCARE SYSTEM | HEALTHCARE SYSTEM OF INDIA | NEWS | BLOGS | IPHARMACENTER

Badari Andukuri

Sep 1

FDA Approves Takeda’s MIMRYLO for Polycythemia Vera | iPharmaCenter

FDA Approves Takeda’s MIMRYLO for Polycythemia Vera | iPharmaCenter

FDA Approves Takeda’s MIMRYLO for Polycythemia Vera | iPharmaCenter

Badari Andukuri

Aug 30

FDA Approves Revolution Medicines’ RASONQUE for Metastatic Pancreatic Cancer | iPharmaCenter

FDA Approves Revolution Medicines’ RASONQUE for Metastatic Pancreatic Cancer | iPharmaCenter

FDA Approves Revolution Medicines’ RASONQUE for Metastatic Pancreatic Cancer | iPharmaCenter

Badari Andukuri

Aug 27

China: NMPA Approves New Therapies | 2026

China: NMPA Approves New Therapies | 2026

China: NMPA Approves New Therapies | 2026

Badari Andukuri

Aug 26

FDA Approves Johnson and Johnson’s IMAAVY for Warm Autoimmune Hemolytic Anemia | iPharmaCenter

FDA Approves Johnson and Johnson’s IMAAVY for Warm Autoimmune Hemolytic Anemia | iPharmaCenter

FDA Approves Johnson and Johnson’s IMAAVY for Warm Autoimmune Hemolytic Anemia | iPharmaCenter

Badari Andukuri

Aug 26

Japan Approves GSK’s Hibsago for Chronic Hepatitis B and Takeda’s Orzeyful for Narcolepsy Type 1

Japan Approves GSK’s Hibsago for Chronic Hepatitis B and Takeda’s Orzeyful for Narcolepsy Type 1

Japan Approves GSK’s Hibsago for Chronic Hepatitis B and Takeda’s Orzeyful for Narcolepsy Type 1

Badari Andukuri

Aug 24

bottom of page